Trial Profile
A Phase II Open-label Multicenter Exploratory Study to Assess Efficacy of Pembrolizumab Re-challenge as Second or Further Line in Patients With Advanced Non - Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms Replay
- 03 Apr 2023 Status changed from recruiting to enrolment to completed.
- 09 Jan 2023 Planned End Date changed from 15 Dec 2023 to 15 Mar 2023.
- 09 Jan 2023 Planned primary completion date changed from 15 Dec 2022 to 28 Feb 2023.